# A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

Source: https://onco.cc/trials/nct05667506/  
OnCo record `nct05667506` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of single dose of CNCT19 in acute lymphoblastic leukaemia, run by Juventas Cell Therapy Ltd., now recruiting.

## Summary

A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) is a phase 1/2 interventional study registered as NCT05667506 by Juventas Cell Therapy Ltd., with 47 participants planned, started 2023-02-07 and due to reach its primary completion in 2025-05-30. Interventions recorded: single dose of CNCT19.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05667506
- Phase: 1/2
- Setting: A Phase Ib/II, Single Arm, Multi-center Study Evaluating the Safety and Efficacy of CNCT19 in Children and Adolescent(Pediatric) Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)
- Sponsor: Juventas Cell Therapy Ltd.
- Enrolled: 47

## Sources

- ClinicalTrials.gov NCT05667506: https://clinicaltrials.gov/study/NCT05667506

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)

---
JSON: https://onco.cc/api/v1/entities/nct05667506.json